| 5.085 -0.265 (-4.95%) | 07-31 10:51 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 7.28 | 1-year : | 8.29 |
| Resists | First : | 6.24 | Second : | 7.09 |
| Pivot price | 5.41 |
|||
| Supports | First : | 4.84 | Second : | 4.03 |
| MAs | MA(5) : | 5.19 |
MA(20) : | 5.66 |
| MA(100) : | 6.6 |
MA(250) : | 4.43  |
|
| MACD | MACD : | -0.4 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 19.3 |
D(3) : | 20.1 |
| RSI | RSI(14): 35.4 |
|||
| 52-week | High : | 8 | Low : | 0.55 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ RLMD ] has closed above bottom band by 31.0%. Bollinger Bands are 14.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.43 - 5.46 | 5.46 - 5.48 |
| Low: | 5.13 - 5.15 | 5.15 - 5.18 |
| Close: | 5.3 - 5.35 | 5.35 - 5.39 |
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Thu, 30 Jul 2026
Relmada Therapeutics Inc (RLMD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Wed, 29 Jul 2026
BlackRock (NYSE: BLK) discloses 7.0% beneficial stake in Relmada Therapeutics (RLMD) - Stock Titan
Tue, 28 Jul 2026
Relmada Therapeutics (RLMD) Names Bipin Dalmia as Chief Business Officer Amid Strategic Growth Focus - GuruFocus
Tue, 28 Jul 2026
Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer - GlobeNewswire
Tue, 28 Jul 2026
Relmada hires executive with U.S. bladder cancer gene therapy experience - Stock Titan
Mon, 27 Jul 2026
Relmada Therapeutics Inc (RLMD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 105 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 2.9 (%) |
| Held by Institutions | 91.4 (%) |
| Shares Short | 12,990 (K) |
| Shares Short P.Month | 6,060 (K) |
| EPS | -1.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.14 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -14.4 % |
| Return on Equity (ttm) | -25.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.14 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -4.66 |
| PEG Ratio | 0 |
| Price to Book value | 0.49 |
| Price to Sales | 0 |
| Price to Cash Flow | -44.03 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|